全文获取类型
收费全文 | 94196篇 |
免费 | 9447篇 |
国内免费 | 4628篇 |
专业分类
耳鼻咽喉 | 2117篇 |
儿科学 | 332篇 |
妇产科学 | 2994篇 |
基础医学 | 10429篇 |
口腔科学 | 3389篇 |
临床医学 | 6713篇 |
内科学 | 11605篇 |
皮肤病学 | 2007篇 |
神经病学 | 208篇 |
特种医学 | 4233篇 |
外国民族医学 | 122篇 |
外科学 | 13802篇 |
综合类 | 16772篇 |
现状与发展 | 23篇 |
预防医学 | 2180篇 |
眼科学 | 390篇 |
药学 | 4736篇 |
15篇 | |
中国医学 | 1191篇 |
肿瘤学 | 25013篇 |
出版年
2024年 | 49篇 |
2023年 | 1312篇 |
2022年 | 2064篇 |
2021年 | 3588篇 |
2020年 | 3224篇 |
2019年 | 3064篇 |
2018年 | 2945篇 |
2017年 | 3333篇 |
2016年 | 3747篇 |
2015年 | 4306篇 |
2014年 | 6410篇 |
2013年 | 5603篇 |
2012年 | 5819篇 |
2011年 | 6259篇 |
2010年 | 4996篇 |
2009年 | 4996篇 |
2008年 | 5167篇 |
2007年 | 5413篇 |
2006年 | 5053篇 |
2005年 | 4500篇 |
2004年 | 3588篇 |
2003年 | 3101篇 |
2002年 | 2655篇 |
2001年 | 2539篇 |
2000年 | 2147篇 |
1999年 | 1659篇 |
1998年 | 1426篇 |
1997年 | 1231篇 |
1996年 | 1119篇 |
1995年 | 1067篇 |
1994年 | 973篇 |
1993年 | 679篇 |
1992年 | 596篇 |
1991年 | 518篇 |
1990年 | 444篇 |
1989年 | 385篇 |
1988年 | 363篇 |
1987年 | 290篇 |
1986年 | 236篇 |
1985年 | 263篇 |
1984年 | 214篇 |
1983年 | 153篇 |
1982年 | 175篇 |
1981年 | 149篇 |
1980年 | 144篇 |
1979年 | 109篇 |
1978年 | 76篇 |
1977年 | 52篇 |
1976年 | 44篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《European journal of surgical oncology》2022,48(5):1062-1067
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease. 相似文献
3.
4.
Xi Tian Yue Wang Wenhao Xu Haidan Tang Shuxuan Zhu Aihetaimujiang Anwaier Wangrui Liu Wenfeng Wang Wenkai Zhu Jiaqi Su Yuanyuan Qu Hailiang Zhang Dingwei Ye 《International journal of cancer. Journal international du cancer》2023,152(1):66-78
In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with everolimus or nivolumab) were downloaded from public databases. Proteomic profiles of 232 ccRCC samples were obtained from Fudan University Shanghai Cancer Center (FUSCC). Biological changes, tumor microenvironment and prognostic differences were explored between samples with various glycolysis characteristics. There were significant differences in CD8+ effector T cells, epithelial-to-mesenchymal transition and pan-fibroblast TGFb between the Low and High glyScore groups. The tumor mutation burden of the Low glyScore group was lower than that of the High glyScore group. And higher glyScore was significantly associated with worse overall survival (OS) in 768 ccRCC patients (P < .0001). External validation in FUSCC cohort also indicated that glyScore was of strong ability for predicting OS (P < .05). GlyScore may serve as a biomarker for predicting everolimus response in ccRCC patients due to its significant associations with progression-free survival (PFS). And glyScore may also predict overall survival in patients treated with nivolumab. We calculated the glyScore in ccRCC and the defined glyScore was of strong ability for predicting OS. In addition, glyScore may also serve as a biomarker for predicting PFS in patients treated with everolimus and could predict OS in patients treated with nivolumab. 相似文献
5.
6.
肝细胞癌(HCC)是最常见的恶性肿瘤之一。尽管在早期诊断和个体化治疗方面取得了进展,但经根治性切除等治疗后,HCC患者的临床预后仍不佳,复发率高。因此,在HCC患者中识别准确可靠的预后标志物是必要的。作为一种新的免疫营养生物标志物,控制营养状态(CONUT)评分已被报道用于预测癌症患者的预后。本文将对术前CONUT评分与HCC肝切除术后预后的研究进展进行综述。 相似文献
7.
8.
9.
10.
目的:挖掘并筛选与甲状腺乳头状癌(papillary thyroid carcinoma,PTC)淋巴结转移相关的突变基因及其潜在的机制。方法:从TCGA数据库获得377例PTC患者的测序数据及完整的临床资料,并分为淋巴结转移组(LM,n=212)与无淋巴结转移组(NLM,n=165)。利用R语言(v3.6.2)对转移组特有的突变基因进行富集分析。采用String在线软件绘制蛋白互作网络,Cytoscape软件筛选网络中的核心基因。在UALCAN网站上验证基因表达量与淋巴结转移之间的关系。利用荧光实时定量PCR测定候选基因在细胞系中mRNA的表达量。结果:一共筛选出1197个仅在LM组发生突变的基因,它们主要富集在黏着连接、细胞黏附分子(cell adhesion molecules,CAMs)通路。CAMs通路的核心基因ITGB1与VCAN的表达量与淋巴结转移相关。与正常甲状腺细胞系相比,VCAN基因在PTC细胞系TPC-1和B-CPAP中mRNA的表达量较高,尤其是B-CPAP细胞系。结论:CAMs通路可能是PTC淋巴结转移相关机制之一,其中VCAN基因可能是潜在的分子标志物。 相似文献